Healthcare Leaders Hub

🏠Home 📰News 📝Blog 🎬Videos Advertise Login

Your trusted source for pharmaceutical news, expert insights, and healthcare innovation.

💼𝕏 👥▶️

Content

📰News
📝Blog
🎬Videos

Company

🏠Home
🏢About Us
📧Contact

© 2026 PharmaVoice. All rights reserved. Empowering healthcare leaders.

Privacy Policy•Terms of Service

Pharma Tech

FDA grants RPDD to ReviR’s RTX-117 for CMT

Aug 27, 2026, 10:36 AM

Read Full Article → FDA grants RPDD to ReviR’s RTX-117 for CMT

FDA grants RPDD to ReviR’s RTX-117 for CMT

Translate article text

Choose a language and wait for the translated text.

ReviR Therapeutics has received a RPDD from the US FDA for RTX-117, its investigational oral small-molecule therapy for CMT.

FDA grants RPDD to ReviR’s RTX-117 for CMT | PharmaVoice